Search Result

Results for "

AD diseases

" in MedChemExpress (MCE) Product Catalog:

標的別:	11β-HSD (2) 17β-HSD (1) 5-HT Receptor (12) Acetyl-CoA Carboxylase (1) Acyltransferase (1) Adrenergic Receptor (2) Akt (1) Aldose Reductase (1) AMPK (3) Amyloid-β (89) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apolipoprotein (3) Apoptosis (28) Arginase (2) Arrestin (1) Autophagy (7) Bacterial (9) Bcl-2 Family (1) Bcr-Abl (2) Beta-secretase (23) Biochemical Assay Reagents (3) c-Fms (1) Calcium Channel (6) Cannabinoid Receptor (2) Carbonic Anhydrase (6) Casein Kinase (4) Caspase (2) Cathepsin (2) CCR (3) CD22 (1) CDK (6) Cholinesterase (ChE) (113) COX (2) Cytochrome P450 (1) Deubiquitinase (1) Dopamine Transporter (2) Drug Derivative (3) Drug Intermediate (4) Drug Isomer (1) Dynamin (1) DYRK (3) E1/E2/E3 Enzyme (2) ELOVL (1) Endogenous Metabolite (25) Environmental Pollutants (4) ERK (6) FAAH (1) Ferroptosis (3) Fluorescent Dye (5) Free Fatty Acid Receptor (3) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) GABA Receptor (1) Glucocorticoid Receptor (4) GLUT (1) Glutathione Peroxidase (1) Glycosidase (1) GPR55 (2) GSK-3 (16) HDAC (5) Histamine Receptor (3) Histone Demethylase (1) Histone Methyltransferase (2) HIV (1) HSP (3) IAP (1) iGluR (10) Interleukin Related (16) IRAK (2) Isotope-Labeled Compounds (23) JNK (4) Keap1-Nrf2 (7) LDLR (1) Ligands for Target Protein for PROTAC (1) LRRK2 (1) mAChR (6) MAGL (1) MDM-2/p53 (1) mGluR (2) MicroRNA (1) Microtubule/Tubulin (7) Mitochondrial Metabolism (5) MMP (2) Monoamine Oxidase (22) mTOR (2) nAChR (7) NADPH Oxidase (1) Neuropeptide S Receptor (2) Neuropeptide Y Receptor (3) NF-κB (8) NO Synthase (2) NOD-like Receptor (NLR) (12) Nuclear Factor of activated T Cells (NFAT) (1) Nuclear Hormone Receptor 4A/NR4A (2) OGA (2) p38 MAPK (4) p62 (2) Parasite (4) Phosphodiesterase (PDE) (10) Phospholipase (3) PI3K (1) PKA (1) PPAR (4) Prion Protein (1) Prostaglandin Receptor (1) PROTACs (3) Proteasome (3) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (10) Reference Standards (27) RIP kinase (1) Sirtuin (1) Small Interfering RNA (siRNA) (2) SOD (1) Sodium Channel (1) Survivin (1) Syk (1) Tau Protein (28) TGF-β Receptor (1) Thymidylate Synthase (3) TNF Receptor (7) Toll-like Receptor (TLR) (1) TREM receptor (1) Trk Receptor (4) TRP Channel (6) Vasopressin Receptor (1) Wnt (8) α-synuclein (6) β-catenin (7) γ-secretase (13)
研究分野別:	Cancer (31) Cardiovascular Disease (11) Endocrinology (10) Infection (16) Inflammation/Immunology (62) Metabolic Disease (22) Neurological Disease (400)
クリックケミストリー:	Alkynes (2)

435

阻害剤およびアゴニスト

スクリーニングライブラリ

蛍光色素

生化学アッセイ試薬

ペプチド

阻害性抗体

天然物

同位体標識化合物

クリックケミストリー

製品番号	製品名	Target	研究分野	構造式

HY-B0591

Memantine 5+ Cited Publications	iGluR	Neurological Disease
Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD) .

HY-50682

Azeliragon 10+ Cited Publications TTP488; PF-04494700	Amyloid-β	Neurological Disease Cancer
Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-132831

Selnoflast 1 Publications Verification Somalix; RO-7486967; IZD334	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .

HY-P0198

Neuropeptide Y (human,rat,mouse) 3 Publications Verification Neuropeptide Y (29-64), amide	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human,rat,mouse) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-109055

Elenbecestat 1 Publications Verification E2609	Beta-secretase	Neurological Disease
Elenbecestat (E2609) is a potent, orally bioavailable and BBB-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research .

HY-P1389

Neuropeptide S (human)	Neuropeptide S Receptor	Neurological Disease
Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research .

HY-N0702

Tenuifolin	Beta-secretase Cholinesterase (ChE)	Neurological Disease
Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD).

HY-19369

L-685458 5+ Cited Publications L-685,458	γ-secretase Apoptosis	Neurological Disease Cancer
L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC₅₀ of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC₅₀s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .

HY-11013

ZSET1446 ST-101	Calcium Channel nAChR	Neurological Disease Cancer
ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.

HY-105321

PBT 1033 PBT 2	Bacterial	Neurological Disease
PBT 1033 (PBT 2) is an orally active copper/zinc ionophore. PBT 1033 restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

HY-113366

Prostaglandin J2 PGJ2	Prostaglandin Receptor Endogenous Metabolite	Neurological Disease
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-106000

GSK239512	Histamine Receptor	Neurological Disease
GSK239512 is a potent and brain penetrated H₃ receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD) .

HY-107481

Fasoracetam NS 105	mGluR	Neurological Disease
Fasoracetam (NS 105) is the activator of metabotropic glutamate receptor (mGluR). Fasoracetam (NS 105) has the potential for the research of attention-deficit hyperactivity disorder (ADHD) and Alzheimer's disease (AD) .

HY-137315

TML-6	Amyloid-β NF-κB mTOR Keap1-Nrf2	Neurological Disease
TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research .

HY-159838

Enrupatinib EI‐1071	c-Fms Amyloid-β	Neurological Disease Cancer
Enrupatinib (EI‐1071) is a potent, orally active, CNS-penetrant and selective CSF1R inhibitor. Enrupatinib inhibits macrophage proliferation and osteoclast differentiation in vitro. Enrupatinib preserves microglia distal to Aβ plaques. Enrupatinib mitigates Alzheimer's disease (AD)-related pathologies by reducing neuroinflammation, preserving neuronal integrity, lowering disease-associated microglia gene expression, and enhancing cognitive function in 5xFAD and J20 mouse models. Enrupatinib reduces tumor-associated macrophage infiltration and enhances antitumor activity of anti-PD-1 antibody in murine colorectal cancer and breast cancer models. Enrupatinib can be used for the research of AD, colorectal cancer, and breast cancer .

HY-14679

GSK3β inhibitor II	GSK-3	Neurological Disease
GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .

HY-137472

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC₅₀ of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC₅₀ values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-141660

BSc3094	Tau Protein	Neurological Disease
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) .

HY-P0198A

Neuropeptide Y (human,rat,mouse) TFA 3 Publications Verification	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-175352

Nurr1 agonist 14	Nuclear Hormone Receptor 4A/NR4A SOD IAP Survivin Calcium Channel	Neurological Disease
Nurr1 agonist 14 (Compound 32) is a Nurr1 agonist with an EC₅₀ of 0.09  μM for Nurr1. Nurr1 agonist 14 has significant neuroprotective activity with no influence of residual DHODH inhibition. Nurr1 agonist 14 upregulates neuroprotective genes including SOD2, SESN3, BIRC5, XIAP, FLRT2 and CRMP4 in dopaminergic neurons. Nurr1 agonist 14 can be used for neurodegenerative diseases such as Alzheimer′s disease (AD), Parkinson′s disease (PD) and multiple sclerosis (MS) research .

HY-P10557

DAG peptide	Biochemical Assay Reagents	Neurological Disease
DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation .

HY-P1046

β-Amyloid (1-15) Amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-171444

GSM III	γ-secretase Amyloid-β	Neurological Disease
GSM III is a γ-Secretase complexe (GSEC) modulator. GSM III significantly regulates amyloid-β (Aβ) length at the extracellular interface between the protease (NCT, PSEN) and the substrate APP_C99. GSM III can be used for Alzheimer's disease (AD) research .

HY-175022

PROTAC IRAK4 degrader-13	PROTACs IRAK Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
PROTAC IRAK4 degrader-13 (Degrader 1) is a selective IRAK4 PROTAC degrader with DC₅₀s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research . Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P1468

β-Amyloid (1-28) Amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-176852

O-GlcNAcase-IN-3	OGA	Neurological Disease
O-GlcNAcase-IN-3 (Compound I) is an OGA inhibitor. O-GlcNAcase-IN-3 can be used for Alzheimer's Disease (AD) research .

HY-19742A

Lecozotan hydrochloride SRA-333 hydrochloride	5-HT Receptor	Neurological Disease
Lecozotan (SRA-333) hydrochloride is an orally active and selective antagonist of 5-HT_1A with a K_i of 4.5 nM for cloned human 5-HT_1A receptor. Lecozotan hydrochloride enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. Lecozotan hydrochloride has the potential for mild-to-moderate Alzheimer's disease (AD) research .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-117710B

AD-35	Cholinesterase (ChE) Amyloid-β ERK TNF Receptor Interleukin Related	Neurological Disease
AD-35 is an orally active anti-Alzheimer's disease (AD) agent with moderate AChE inhibitory activity and metal ion chelating ability. AD-35 exhibits IC₅₀ values for AChE and BuChE of 793 nM and 31428 nM, respectively. AD-35 can form chelates with Cu²⁺ and Fe³⁺, but its chelating ability for Zn²⁺ is relatively weak. AD-35 can inhibit Aβ aggregation and disassemble the formed Aβ aggregates, and inhibit Aβ-induced ERK phosphorylation. AD-35 inhibits neuroinflammation in AD rat models and demonstrates a strong effect in improving cognitive function .

HY-178323

MW073	5-HT Receptor Arrestin	Neurological Disease
MW073 is a highly selective and orally active 5-HT2BR antagonist (IC₅₀ =70 nM). MW073 exerts its effects by concentration-dependently inhibiting receptor activity and β-arrestin-1 recruitment. MW073 ameliorates synaptic plasticity and behavioral deficits, including aggression, in Alzheimer’s disease (AD) mouse models. MW073 can be used for Alzheimer’s disease (AD) research ^[1][2].

HY-153189

TrkB-IN-1	Trk Receptor	Neurological Disease
TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. TrkB-IN-1 reverses the cognitive defects in an AD mouse model and can be used for alzheimer’s disease research .

HY-105321A

PBT 1033 hydrochloride PBT 2 hydrochloride	Bacterial	Neurological Disease
PBT 1033 hydrochloride is an orally active copper/zinc ionophore. PBT 1033 hydrochloride restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-178454

Multitarget AD-IN-3	Monoamine Oxidase Amyloid-β Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) COX NF-κB	Neurological Disease
Multitarget AD-IN-3 is a brain-penetrant neuroprotective agent. Multitarget AD-IN-3 can selectively inhibit MAO-B with an IC₅₀ of 4.42 μM and a SI of 18.12. Multitarget AD-IN-3 can eliminate ROS. Multitarget AD-IN-3 Multitarget AD-IN-3 can inhibit Aβ_1-42 self-aggregation and can reverse Aβ_1-42-induced mitochondrial membrane depolarization and inhibit apoptosis. Multitarget AD-IN-3 can be used for the research of neurological disease, such as Alzheimer’s disease .

HY-178750

AChE-IN-96	Cholinesterase (ChE)	Neurological Disease
AChE-IN-96 (Compound 8a) is an AChE inhibitor, with an IC₅₀ of 0.697 μM. AChE-IN-96 can be used for the study of neurodegenerative diseases such as Alzheimer's disease (AD) .

HY-132831B

Selnoflast potassium Somalix potassium; RO-7486967 potassium; IZD334 potassium	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Selnoflast potassium (RO7486967 potassium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast potassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast potassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .

HY-W841438

Lithium orotate	Amyloid-β Tau Protein	Neurological Disease
Lithium orotate is an orally active lithium supplement with reduced binding that can bypass amyloid sequestration in AD mice models. Lithium orotate can prevent Aβ plaque deposition and phospho-tau accumulation and reverse AD pathology, neuroinflammatory changes and memory loss in AD mice models and ageing wild-type mice. Lithium orotate can be used for the research of alcoholism and Alzheimer’s disease .

HY-144446

BuChE-IN-1	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-1 (Compound 23) is a potent inhibitor of butyrylcholinesterase (BuChE). Butyrylcholinesterase (BuChE) is recently regarded as a biomarker in progressed Alzheimer’s disease (AD). BuChE-IN-1 shows low cytotoxicity and high blood brain barrier (BBB) permeability. BuChE-IN-1 is a promising BuChE inhibitor for the research of AD .

HY-172427

Elsovaptan	Vasopressin Receptor	Neurological Disease
Elsovaptan is the antagonist for vasopressin receptor that can be used in researchs of Alzheimer disease .

HY-146068

AEP-IN-1	Cathepsin	Neurological Disease
AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC₅₀ of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD) .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P99527

Vanutide cridificar ACC-001; PF 05236806	Amyloid-β	Neurological Disease
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .

HY-173615

KTD-092	DYRK	Neurological Disease Metabolic Disease
KTD-092 is a hit for DYRK1A inhibition, with an IC₅₀ of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases .

HY-112636

Astrophloxine	Amyloid-β	Others
Astrophloxine is a fluorescent imaging probe capable of targeting antiparallel dimers. Astrophloxine can be used to detect aggregated Aβ in brain tissue and cerebrospinal fluid samples of Alzheimer's disease (AD) mice .

HY-175211

BChE-IN-42	Cholinesterase (ChE)	Neurological Disease
BChE-IN-42 (Compound 4a) is a BChE inhibitor with an IC₅₀ of 10.01 nM. BChE-IN-42 can be used for neurological diseases like Alzheimer's disease (AD) research .

HY-175006

AChE-IN-91	Cholinesterase (ChE)	Neurological Disease
AChE-IN-91 (Compound 8u) is a AChE inhibitor with an IC₅₀ of 0.05 μM. AChE-IN-91 has significant anticholinesterase activity, promising for neurological diseases like Alzheimer's disease (AD) research .

製品番号	製品名

HY-L069

Anti-Alzheimer's Disease Compound Library

2,065 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 2,065 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L028

CNS-Penetrant Compound Library

1,096 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L086

Neurodegenerative Disease-related Compound Library

3,545 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 3,545 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L134

Anti-Aging Natural Product Library

193 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

HY-L010

MAPK Compound Library

1,063 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 1,063 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

HY-L037

Antioxidant Compound Library

2,332 compounds

Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.

MCE Antioxidant Compound Library contains 2,332 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

HY-L068

Flavonoids Library

576 compounds

Flavonoids are an important class of natural products; particularly, they belong to a class of plant secondary metabolites having a polyphenolic structure, widely found in fruits, vegetables and certain beverages. Flavonoids can be subdivided into different subgroups depending on the carbon of the C ring on which the B ring is attached and the degree of unsaturation and oxidation of the C ring. These subgroups are: flavones, flavonols, flavanones, flavanonols, flavanols or catechins, anthocyanins and chalcones. Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function. Naturally occurring flavonoids are known to have biological activities for use as drugs, for example, in diseases like cancer, Alzheimer’s disease (AD), atherosclerosis, etc.

MCE offers a unique collection of 576 natural flavonoid compounds which is a useful tool for drug discovery as an important source of lead compounds.

製品番号	製品名	Type

HY-111263

NIAD-4 1 Publications Verification	蛍光色素
NIAD-4 is a blood-brain barrier permeable fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM .

HY-D3171

AD-BChE/HClO

蛍光色素

AD-BChE/HClO is a dual-target two-photon fluorescent probe. AD-BChE/HClO can release 4-methylumbelliferone via butyrylcholinesterase-mediated hydrolysis of the ester bond at position 7, as well as hypochlorous acid-mediated thiocarbonyl oxidation. AD-BChE/HClO enables two-photon imaging in nerve cells and mouse brain tissues via tail vein injection. AD-BChE/HClO can be used for the research of Alzheimer's disease .

HY-D2967

Golgi-NO	蛍光色素
Golgi-NO is a Golgi-targeted fluorescent probe for nitric oxide (NO) (Ex/Em: 560 nm/589 nm). Golgi-NO exhibits excellent selectivity for various potential interfering substances. Golgi-NO can be used to study the function of NO within the Golgi apparatus in disease models such as Alzheimer's disease (AD) .

HY-12879G

IWP-4

蛍光色素

IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

製品番号	製品名	Type

HY-15908

BCA 5+ Cited Publications Disodium bicinchoninate	生化学アッセイ試薬
BCA (Disodium bicinchoninate) is an orally active and non-competitive Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ value of 28 µM, a K_i value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .

HY-Y0808

Dimethyl succinate

1 Publications Verification

生化学アッセイ試薬

Dimethyl succinate is an orally active cell permeable succinate analogue. Dimethyl succinate can disrupt the TCA cycle by elevating intracellular succinate levels, leading to reduced protein synthesis and impairs myogenic differentiation. Dimethyl succinate can induce apoptosis. Dimethyl succinate can decrease maximal cellular respiration and reserve capacity. Dimethyl succinate can rescue synapse loss in AD. Dimethyl succinate can be used for the researches of metabolic and neurological disease ^[1][2].

HY-NP0204

Mouse Serum Albumin

生化学アッセイ試薬

Mouse Serum Albumin is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD) .

HY-12879G

IWP-4

生化学アッセイ試薬

製品番号	製品名	Target	研究分野

HY-P0175

740 Y-P Maximum Cited Publications 241 Publications Verification 740YPDGFR; PDGFR 740Y-P	PI3K Autophagy	Cancer
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-P0198

Neuropeptide Y (human,rat,mouse) 3 Publications Verification Neuropeptide Y (29-64), amide	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human,rat,mouse) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P1389

Neuropeptide S (human)	Neuropeptide S Receptor	Neurological Disease
Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research .

HY-P6306

CS-6253 1 Publications Verification	Apolipoprotein Amyloid-β	Neurological Disease Metabolic Disease
CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .

HY-P1466

β-Amyloid (1-16) Amyloid β-Protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P5381

gp91 ds-tat 1 Publications Verification	NADPH Oxidase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase TRP Channel	Cardiovascular Disease Neurological Disease Inflammation/Immunology
gp91 ds-tat, a biological active peptide, is a NADPH oxidase 2 (Nox2) inhibitor. gp91 ds-tat blocks NADPH oxidase-dependent superoxide production. gp91 ds-tat ameliorates high glucose-induced increase in total ROS, LPOs and iron levels. gp91 ds-tat inhibits homocysteine (Hcy)-induced activation of NLRP3 inflammasomes and restores Hcy-inhibited lysosomal TRPML1 channel activity. gp91 ds-tat improves cerebrovascular and cognitive function in APP/PS1 mice. gp91 ds-tat can be used for the study of Alzheimer’s disease (AD), glomerular inflammation and cardiovascular disease .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.

HY-P0198A

Neuropeptide Y (human,rat,mouse) TFA 3 Publications Verification	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P4882A

(Pyr3)-Amyloid β-Protein (3-42) TFA	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P10557

DAG peptide	Biochemical Assay Reagents	Neurological Disease
DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation .

HY-P1046

β-Amyloid (1-15) Amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1387

β-Amyloid (1-40) (rat)	Amyloid-β Apoptosis	Neurological Disease
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases ⁴⁵Ca ²⁺ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P1468

β-Amyloid (1-28) Amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P6306A

CS-6253 TFA 1 Publications Verification	Apolipoprotein Amyloid-β	Neurological Disease Metabolic Disease
CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P3780

Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .

HY-P4882

(Pyr3)-Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P1378

β-Amyloid (1-43)(human)	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P11319

RAP-103	CCR	Neurological Disease
RAP-103 is an orally active CCR antagonist that provides potent synaptic protection by inhibiting and reversing cytoskeletal changes induced by PrPC/NOX signaling. RAP-103 is potentially useful in Alzheimer's disease (AD) research .

HY-P3528

GPR	Caspase Apoptosis	Neurological Disease
GPR is a three amino acid peptide. GPR can rescue cultured rat hippocampal neurons from Aβ-induced neuronal death by inhibiting caspase-3/p53 dependent apoptosis. GPR can be used for the research of Alzheimer's disease (AD).

HY-P10942

CGN peptide	Small Interfering RNA (siRNA)	Neurological Disease
CGN peptide is a 13 amino acid peptide composed of D-amino acids, referred to as CGN peptide. CGN peptide is the retro-inverso isomer of the l-peptide TGN (TGNYKALHPHNG) and can deliver siRNA to the blood-brain barrier (BBB). CGN peptide can be used in Alzheimer's disease (AD) research .

HY-P10942A

CGN peptide TFA	Small Interfering RNA (siRNA)	Neurological Disease
CGN peptide TFA is a 13 amino acid peptide composed of D-amino acids, referred to as CGN peptide. CGN peptide TFA is the retro-inverso isomer of the l-peptide TGN (TGNYKALHPHNG) and can deliver siRNA to the blood-brain barrier (BBB). CGN peptide TFA can be used in Alzheimer's disease (AD) research .

HY-P10487

APP669-711	Amyloid-β	Neurological Disease
APP669-711 is a peptide segment from amino acid 669 to amino acid 711 of amyloid precursor protein (APP). APP669-711 can be used to diagnose the amyloid deposition in the brain, and is a biomarker for Alzheimer's disease (AD) research .

HY-P1389A

Neuropeptide S (human) TFA	Neuropeptide S Receptor	Neurological Disease
Neuropeptide S human TFA, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human TFA can be used for Alzheimer's disease (AD) research .

HY-P3781

(Met(O)35)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .

HY-P2473

Neurogranin (48-76), human	ペプチド	Neurological Disease
Neurogranin (48-76), human is a dominant endogenous peptide in Alzheimer's disease (AD) brain tissue. Neurogranin (48-76) is a potential biomarker for synaptic function in AD .

HY-P11047

QSH peptide	Amyloid-β	Neurological Disease
QSH peptide is a peptide that specifically binds to Aβ1-42 and is used in the synthesis of siRNA delivery complexes. QSH peptide can be used in Alzheimer's disease (AD) research .

HY-P0198B

[D-Arg25]-Neuropeptide Y (human)	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease
[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y₁ receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity .

HY-P10037

β Amyloid(17-28) human	Amyloid-β	Neurological Disease
β Amyloid(17-28) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid(17-28) human enhances aggregation of full-length β Amyloid40, producing toxic aggregates in Alzheimer's disease (AD) .

HY-P10630

Pep63	Amyloid-β	Neurological Disease
Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research .

HY-P10674

QMT-CBT	Biochemical Assay Reagents	Neurological Disease
QMT-CBT is a near-infrared aggregation-induced luminescent photon. After activation of caspase1 (Cas1), QMT-CBT undergoes a CBT-Cys click reaction to form a cyclic dimer QMT-Dimer (the first aggregate) and assembles into nanoparticles (the second aggregate), turning the AIE signal "on" to enhance imaging of Alzheimer's disease (AD) .

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .

HY-P4899

β-Secretase substrate VI, fluorogenic RE(EDANS)EVNLDAEFK(DABCYL)R	Beta-secretase	Neurological Disease
β-Secretase substrate VI, fluorogenic is an EDANS and DABCYL double-labeled peptide，serves as a fluorescent substrate for BACE1(Em=360nm，Ex=528nm). β-Secretase substrate VI, fluorogenic can be used for BACE1 activity measurement and the enzyme activity level is directly proportional to the fluorescence reaction .

HY-P10247

Amyloid precursor C-terminal peptide	Mitochondrial Metabolism	Neurological Disease
Amyloid precursor C-terminal peptide is cleaved from the C-terminus of Amyloid Precursor Protein (APP). Amyloid precursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloid precursor protein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .

HY-P11677

CPO_Aβ17-21P		Neurological Disease
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC₅₀ of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .

HY-P1389S

Neuropeptide S (human)-13C2,15N	Isotope-Labeled Compounds	Neurological Disease
Neuropeptide S (human)- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled Neuropeptide S (human) (HY-P1389). Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research .

製品番号	製品名	Target	研究分野	Image

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows blood-brain-barrier penetration, and can be used for Alzheimer's disease (AD) research .

HY-P99673

Itepekimab 1 Publications Verification REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

HY-P99185

Bapineuzumab AAB-001	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P991413

ZEB85	Trk Receptor ERK Akt p38 MAPK	Neurological Disease Inflammation/Immunology
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .

HY-P99163

Tilavonemab ABBV-8E12; C2N-8E12	Tau Protein	Neurological Disease
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .

HY-P9995

Posdinemab JNJ-63733657	Tau Protein	Neurological Disease
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .

HY-P991373

APNmAb005	Tau Protein	Neurological Disease
APNmAb005 is a human monoclonal antibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research .

HY-P990283

Anti-Mouse CD22 Antibody (Cy34.1)	CD22	Neurological Disease Inflammation/Immunology
Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD22. Anti-Mouse CD22 Antibody (Cy34.1) can deplete CD22 cells and B cells. Anti-Mouse CD22 Antibody (Cy34.1) can promote microglial phagocytosis. Anti-Mouse CD22 Antibody (Cy34.1) can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease (AD) and neuromyelitis .

HY-P990221

Anti-Mouse IL-17F Antibody (MM17F8F5.1A9)	Interleukin Related	Infection Neurological Disease Cancer
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-17F. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can neutralize IL-17. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can be used for the researches of cancer, infection and neurological disease, such as Alzheimer’s disease (AD) and pancreatic cancer .

HY-P99527

Vanutide cridificar ACC-001; PF 05236806	Amyloid-β	Neurological Disease
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .

HY-P991376

BIIB076	Tau Protein	Neurological Disease
BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD) .

HY-P991377

TBL-100	Tau Protein	Neurological Disease
TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .

HY-P990167

Anti-Mouse/Human PrP/prion protein Antibody (TW1)	Prion Protein Tau Protein	Neurological Disease
Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human PrP/prion protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) binds to both PrPc (cellular prion protein) and PrPSc (Scrapie Prion Protein) and blocks the interaction of prion protein with tau protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) can be used for the researches of Alzheimer’s disease (AD) .

HY-P99648A

Gosuranemab (powder) BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)	Tau Protein	Neurological Disease
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .

製品番号	製品名	Category	Target	構造式

HY-16569

Colchicine Maximum Cited Publications 62 Publications Verification	Structural Classification 天然物 other families Classification of Application Fields Plants Disease Research Fields Source Classification Cancer	Environmental Pollutants Apoptosis Autophagy Microtubule/Tubulin NOD-like Receptor (NLR)
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .

HY-10863

Anandamide 2 Publications Verification AEA; Arachidonoyl ethanolamide	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-113354

Anserine 5 Publications Verification	Structural Classification Immune System Disorder Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Endogenous metabolite Source Classification	Endogenous Metabolite
Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine has blood-brain barrier permeability, and improves memory functions in Alzheimer's disease (AD)-model mice .

HY-N2922

β-Amyrin	Monophenols Celastrus hindsii Benth. Celastraceae Phenols Plants	Amyloid-β NF-κB
β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound .

HY-D0186

2'-Deoxyuridine 3 Publications Verification	Infection 天然物 Immune System Disorder Microorganisms Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Thymidylate Synthase
2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .

HY-N0028

Forsythiaside A 5 Publications Verification	Oleaceae Classification of Application Fields Simple Phenylpropanols Phenols Polyphenols Phenylpropanoids Forsythia suspensa (Thunb.) Vahl Plants Inflammation/Immunology Disease Research Fields Source Classification	Others
Forsythiaside A is an orally active phenylethanoid glycoside isolated from the dried fruits of Forsythia suspensa. Forsythiaside A is also an inhibitor of COX-2 and has anti-inflammatory, antioxidant and neuroprotective effects. Forsythiaside A prevents neuroinflammation and apoptosis caused by Aβ_25-35 damage and may be used in Alzheimer's disease (AD) research. Forsythiaside A also activates the Nrf2/HO-1 signaling pathway and inhibits OVA-induced asthma in mice. Forsythiaside A inhibits the interaction between KLRB1 and CLEC2D .

HY-N0702

Tenuifolin	Triterpenes Terpenoids Polygalaceae Plants Polygala tenuifolia Willd. Source Classification	Beta-secretase Cholinesterase (ChE)
Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD).

HY-N0710

alpha-Cyperone 3 Publications Verification α-Cyperone; (+)-α-Cyperone	other families Classification of Application Fields Terpenoids Sesquiterpenes Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
alpha-Cyperone (α-Cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1, resulting in reduction of inflammation, which would be highly beneficial for treatment of inflammatory diseases such as AD.

HY-N0740

Jatrorrhizine chloride 3 Publications Verification	Alkaloids Monophenols Coptis chinensis Franch. Ranunculaceae Phenols Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0611

alpha-Boswellic acid 1 Publications Verification α-Boswellic acid	Triterpenes Classification of Application Fields Terpenoids Boswellia serrata Plants Burseraceae Inflammation/Immunology Disease Research Fields Source Classification	Others
alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .

HY-Y0399

L-Norvaline Norvaline	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Amyloid-β TNF Receptor Arginase
L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .

HY-A0009

Galanthamine hydrobromide 10+ Cited Publications Galantamine hydrobromide	Alkaloids Other Alkaloids Plants Amaryllidaceae	Cholinesterase (ChE) nAChR
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-113366

Prostaglandin J2 PGJ2	Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-N3383

Ligustroside Ligstroside	Monophenols Iridoids Ligustrum japonicum Thunb. Oleaceae Terpenoids Phenols Plants Source Classification	Mitochondrial Metabolism
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages .

HY-107577

Gedunin	Infection Triterpenes other families Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent Hsp90 inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-106353

Smilagenin 1 Publications Verification	Structural Classification Liliaceae Pelargonium hortorum Bailey Neurological Disease Classification of Application Fields Anemarrhena asphodeloides Bunge Plants Geraniaceae Disease Research Fields Steroids	mAChR Endogenous Metabolite
Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .

HY-N0222

Avicularin 5+ Cited Publications	Flavonols Flavonoids Classification of Application Fields Phenols Polyphenols Plants Lauraceae Lindera aggregata (Sims) Kosterm. Inflammation/Immunology Disease Research Fields Source Classification	COX NF-κB PPAR ERK GLUT Apoptosis
Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities .

HY-N0749

Jatrorrhizine	Alkaloids Monophenols other families Phenols Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-B1804

Tricaprilin Trioctanoin; Glyceryl trioctanoate	天然物 Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-N2807

Acanthoside B	Monophenols Cistanche salsa (C. A. Mey.) G. Beck Lignans Phenols Orobanchaceae Phenylpropanoids Plants Source Classification	Others
Acanthoside B is a potential bioactive lignan with anti-inflammatory and anti-amnesic activities. Acanthoside B can be used for alzheimer's disease and lung inflammation research

HY-N0812

Timosaponin BII 2 Publications Verification Prototimosaponin A III	Liliaceae Neurological Disease Classification of Application Fields Anemarrhena asphodeloides Bunge Plants Inflammation/Immunology Disease Research Fields Steroids Source Classification	Amyloid-β
Timosaponin BII (Prototimosaponin A III) is a steroid saponin found in the rhizomes of Anemarrhena asphodeloides. Timosaponin BII has neuronal protective, anti-inflammatory and antioxidant activities .

HY-W009081

Tricosanoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Free Fatty Acid Receptor
Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-N0749A

Jatrorrhizine hydroxide 3 Publications Verification	Alkaloids Monophenols Coptis chinensis Franch. Ranunculaceae Phenols Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine hydroxide is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine hydroxide reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-116753

(-)Clausenamide	Clausena lansium (Lour.) Skeels Rutaceae Plants Source Classification	Amyloid-β Tau Protein
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .

HY-W015515

L-Citronellol (S)-3,7-Dimethyloct-6-en-1-ol	Zanthoxylum bungeanum Maxim. Structural Classification Other Monoterpenes Terpenoids Rutaceae Plants Source Classification	Environmental Pollutants TNF Receptor Beta-secretase γ-secretase ERK Cholinesterase (ChE)
L-Citronellol ((S)-3,7-Dimethyloct-6-en-1-ol) is a natural product with anti-allergic and neuroprotective effects. L-Citronellol inhibits mast cell activation and the release of inflammatory factors by inhibiting the ERK pathway. L-Citronellol inhibits BACE1/PSEN1 and AChE, reduces TNF-α expression and lipid peroxidation, demonstrating the potential of multi-target anti-Alzheimer's disease (AD) .

HY-N10423

Cubebin (-)-Cubebin	Structural Classification Classification of Application Fields Lignans Piperaceae Piper cubeba L.f. Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Cholinesterase (ChE) Bacterial Fungal Parasite p38 MAPK
Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .

HY-16569R

Colchicine (Standard)	Structural Classification 天然物 other families Plants Source Classification	Reference Standards Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis
Colchicine (Standard) is the analytical standard of Colchicine. This product is intended for research and analytical applications. Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .

HY-N10488

BChE-IN-11	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Polyphenols Plants Source Classification	Cholinesterase (ChE)
BChE-IN-11 (compound 10) is a potent, selective and non-competitive BChE (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

HY-W015515R

L-Citronellol (Standard) (S)-3,7-Dimethyloct-6-en-1-ol (Standard)	Zanthoxylum bungeanum Maxim. Structural Classification Other Monoterpenes Terpenoids Rutaceae Plants Source Classification	Reference Standards ERK Beta-secretase γ-secretase Cholinesterase (ChE) TNF Receptor
L-Citronellol ((S)-3,7-Dimethyloct-6-en-1-ol) is an analytical standard for L-Citronellol (HY-W015515). This product is intended for research and analytical applications. L-Citronellol is a natural product with anti-allergic and neuroprotective effects. L-Citronellol inhibits mast cell activation and the release of inflammatory factors by inhibiting the ERK pathway. L-Citronellol inhibits BACE1/PSEN1 and AChE, reduces TNF-α expression and lipid peroxidation, demonstrating the potential of multi-target anti-Alzheimer's disease (AD).

HY-N11641

Methyl ganoderate A acetonide	Triterpenes Microorganisms Terpenoids Source Classification	Cholinesterase (ChE)
Methyl ganoderate A acetonide, a lanostane triterpene, is a natural product that could be isolated from the fruiting bodies of Ganoderma lucidum. Methyl ganoderate A acetonide is a potent AChE inhibitor with an IC₅₀ value of 18.35 μM. Methyl ganoderate A acetonide can be used in research of Alzheimer’s disease (AD) .

HY-N0710R

alpha-Cyperone (Standard) α-Cyperone (Standard); (+)-α-Cyperone (Standard)	Structural Classification other families Terpenoids Sesquiterpenes Plants Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
alpha-Cyperone (Standard) is the analytical standard of alpha-Cyperone. This product is intended for research and analytical applications. alpha-Cyperone (α-Cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1, resulting in reduction of inflammation, which would be highly beneficial for treatment of inflammatory diseases such as AD.

HY-Y0399R

L-Norvaline (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Amyloid-β Reference Standards TNF Receptor Arginase
L-Norvaline (Standard) is the analytical standard of L-Norvaline (HY-Y0399). This product is intended for research and analytical applications. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .

HY-D0186R

2'-Deoxyuridine (Standard)	Structural Classification 天然物 Immune System Disorder Microorganisms Disease markers Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Thymidylate Synthase
2'-Deoxyuridine (Standard) is the analytical standard of 2'-Deoxyuridine. This product is intended for research and analytical applications. 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) . In Vitro:The interaction between the 2-deoxyuridine and the column increases the duration of retention of 2-deoxyuridine . Gradient elution with sodium acetate buffer-ACN eluent on two ZIC-HILIC homemade columns separates 2-deoxyuridine in under 9 min . In Vivo:2'-Deoxyuridine (34.42 ng/mL, gavage, 15 min) passes the blood-brain barrier (BBB) to enter the hippocampus of mice brain . 2'-Deoxyuridine (20 mg/kg, gavage, daily for 4 weeks) improves cognition and memory loss and attenuates the damage to the hippocampus in Aβ25-35-induced mice model .

HY-N7887

Cassiaside	Seeds of Cassia tora Linn. other families Leguminosae Phenols Polyphenols Plants Source Classification	Beta-secretase
Cassiaside is a naphthopyrone glucoside, shows mixed-type inhibition against BACE1 (IC₅₀=4.45 μM; K_i=9.85 μM). Cassiaside possesses potential anti- Alzheimer's disease (AD) activity .

HY-N12581

Kuwanon U	Flavonoids Flavonones Morus alba L. Plants Moraceae Source Classification	Cholinesterase (ChE)
Kuwanon U is a potent cholinesterase inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-N1524

Quinovic acid	Zygophyllum fabago L. Ketones, Aldehydes, Acids Zygophyllaceae Plants Source Classification	Amyloid-β MDM-2/p53 Apoptosis
Quinovic acid is triterpene. Quinovic acid can ameliorate the Amyloid-β burden, p53 expression and cholesterol accumulation by deterring the oxidative stress through upregulating the Nrf2/HO-1 pathway. Quinovic acid can induce cancer cells apoptosis by upregulating death receptor 5 (DR5). Quinovic acid can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as lung cancer and Alzheimer’s disease (AD) .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	Structural Classification Alkaloids Other Alkaloids Plants Amaryllidaceae Source Classification	nAChR Cholinesterase (ChE) Reference Standards
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-N0702R

Tenuifolin (Standard)	Triterpenes Structural Classification Terpenoids Polygalaceae Plants Polygala tenuifolia Willd. Source Classification	Reference Standards Beta-secretase Cholinesterase (ChE)
Tenuifolin (Standard) is the analytical standard of Tenuifolin. This product is intended for research and analytical applications. Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD) .

HY-N2971

Buxbodine B	Alkaloids Buxaceae Other Alkaloids Buxus macowanii Oliv. Plants Source Classification	Cholinesterase (ChE)
Buxbodine B is an inhibitor for acetylcholinesterase (AChE) with an IC₅₀ of 50 μM. Buxbodine B can be used in research of Alzheimer's disease .

HY-N10487

Bleformin A	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Polyphenols Plants Source Classification	Cholinesterase (ChE)
Bleformin A is a potent BChE inhibitor with an IC₅₀ value of 5.2 μM. Bleformin A is a nature product that could be isolated from Bletilla striata. Bleformin A can be used for research of Alzheimer's disease (AD) .

HY-N0859B

Schisanchinin D	Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Source Classification	NO Synthase
Schisanchinin D is an NO release inhibitor found in the fruits of Schisandra chinensis. Schisanchinin D can inhibit the release of nitric oxide (NO) by lipopolysaccharide (LPS)-activated microglia in primary murine BV2 microglia cells. Schisanchinin D is promising for research of neurodegenerative diseases such as Alzheimer's disease (AD) .

HY-133102

Dihydronarwedine Lycoraminone	Alkaloids Other Alkaloids Narcissus pseudonarcissus L. Plants Amaryllidaceae Source Classification	GSK-3
Dihydronarwedine (Lycoraminone) is the alkaloid. Dihydronarwedine inhibits 39% activity of glycogen synthase kinase-3β (GSK-3β) at a concentration of 10 μM .

HY-N10490

Blestrin D	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Polyphenols Plants Source Classification	Cholinesterase (ChE)
Blestrin D is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

HY-N4027

Hydrangenol 8-O-glucoside Hydrangenol 8-O-β-D-glucopyranoside	Hydrangeaceae Coumarins Phenylpropanoids Plants Source Classification	Cholinesterase (ChE)
Hydrangenol 8-O-glucoside (Hydrangenol 8-O-β-D-glucopyranoside) can be isolated from Hydrangea macrophyllu. Hydrangenol 8-O-glucoside is an AChE inhibitor (IC₅₀: 22.66 μM). Hydrangenol 8-O-glucoside inhibits passive cutaneous anaphylaxis (PCA) reaction .

HY-N10489

BChE-IN-12	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Polyphenols Plants Source Classification	Cholinesterase (ChE)
BChE-IN-12 (compound 12) is a potent butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀ value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

HY-N10486

BChE-IN-10	Bletilla striata (Thunb. ex Murray) Rchb. f. Classification of Application Fields Neurological Disease Orchidaceae Phenols Polyphenols Plants Disease Research Fields Source Classification	Cholinesterase (ChE)
BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

HY-N15450

Undulatine	Alkaloids Crinum moorei Hook. f Other Alkaloids Plants Amaryllidaceae Source Classification	Cholinesterase (ChE)
Undulatine is a potent AChE inhibitor with an IC₅₀ of 7.4 μM. Undulatine is able to cross the BBB by passive permeation and can be used in the study of Alzheimer’s disease .

HY-N10701

AChE/BChE-IN-11	Oleaceae Syringa oblata Lindl. Plants Saccharides Monosaccharides Source Classification	Cholinesterase (ChE)
AChE/BChE-IN-11 (compound 1) is a potent is a dual AChE and BChE inhibitor with IC₅₀ values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research .

HY-N0812R

Timosaponin BII (Standard) Prototimosaponin A III (Standard)	Liliaceae Anemarrhena asphodeloides Bunge Plants Steroids Source Classification	Amyloid-β Reference Standards
Timosaponin BII (Standard) is the analytical standard of Timosaponin BII. This product is intended for research and analytical applications. Timosaponin BII (Prototimosaponin A III) is a steroid saponin found in the rhizomes of Anemarrhena asphodeloides. Timosaponin BII has neuronal protective, anti-inflammatory and antioxidant activities .

HY-N0611R

alpha-Boswellic acid (Standard) α-Boswellic acid (Standard)	Triterpenes Structural Classification Terpenoids Boswellia serrata Plants Burseraceae Source Classification	Reference Standards Others
alpha-Boswellic acid (Standard) is the analytical standard of alpha-Boswellic acid. This product is intended for research and analytical applications. alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .

製品番号	製品名	構造式

HY-18260S

Bisphenol A-d16

Bisphenol A-d₁₆ is the deuterium labeled Bisphenol A . Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-113354S

Anserine-d4
Anserine-d₄ is the deuterium labeled Anserine. Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice .

HY-18260S1

Bisphenol A-d6

Bisphenol A-d₆ is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-18260S6

Bisphenol A-d14

Bisphenol A-d₁₄ is a deuterium labeled Bisphenol A (HY-18260). Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-B1804S

Tricaprilin-13C3

Tricaprilin- ¹³C₃ (Trioctanoin- ¹³C₃) is a ¹³C-labeled Tricaprilin (HY-B1804) . Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-10863S

Anandamide-d8

Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-18260S3

Bisphenol A-d8

Bisphenol A-d₈ is the deuterium labeled Bisphenol A . Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-18260S4

Bisphenol A-d4

Bisphenol A-d₄ is the deuterium labeled Bisphenol A . Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-50682S

Azeliragon-d9
Azeliragon-d₉ (TTP488-d₉) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .

HY-W778990

2-Deoxyuridine-1,2,3,4,5-13C5

2-Deoxyuridine-1,2,3,4,5- ¹³C₅ is the ¹³C-labeled 2'-Deoxyuridine (HY-D0186). 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .

HY-B1588S

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties . Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease . Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD . Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop .Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself .

HY-18260S5

Bisphenol A-d4-1

Bisphenol A-d₄-1 is the deuterium labeled Bisphenol A . Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-B0591S

Memantine-d3 hydrochloride
Memantine-d₃ (hydrochloride) is deuterium labeled Memantine. Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD) .

HY-W739949

Imidaprilat-d3
Imidaprilat-d₃ (6366A-d₃) is deuterium labeled Imidaprilate. Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC₅₀ of 2.6 nM, and is used in the research of hypertensive disease .

HY-B0124S2

Zonisamide-13C6

Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-15662S

Tulathromycin A-d7
Tulathromycin A-d₇ (Tulathromycin-d₇) is deuterium labeled Tulathromycin A. Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC₅₀=0.26 μM) by targeting bacterial ribosome. Tulathromycin A is used for the research of respiratory disease in cattle and swine. Immunomodulatory effects .

HY-17387S1

(-)-Huperzine A-d4 hydrochloride

(-)-Huperzine A-d₄ hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

HY-113354S1

Anserine-d4 hydrochloride

Anserine-d₄ hydrochloride is the deuterium labeled Anserine (HY-113354). Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice .

HY-B0976AS

Fenoterol-d6 hydrobromide
Fenoterol-d₆ (hydrobromide) (Th-1165a-d₆) is the deuterium labeled Fenoterol hydrobromide. Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol hydrobromide is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research .

HY-B1804S1

Tricaprilin-d50

Tricaprilin-d₅₀ (Trioctanoin-d₅₀) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-B1804S2

Tricaprilin-d15

Tricaprilin-d₁₅ (Trioctanoin-d₁₅) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-113050SA

2,3-Diphosphoglyceric acid-d3 ammonium

2,3-Diphosphoglyceric acid-d3 ammonium (2,3-DPG-d3 ammonium) is the deuterium labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

HY-P1389S

Neuropeptide S (human)-13C2,15N
Neuropeptide S (human)- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled Neuropeptide S (human) (HY-P1389). Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research .

HY-178395S

Tricosanoic acid-d45

Tricosanoic acid-d₄₅ is the deuterium labeled Tricosanoic acid (HY-W009081). Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-W746542

Tricosanoic acid-d3

Tricosanoic acid-d₃ is the deuterium labeled Tricosanoic acid (HY-W009081). Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-W751808S

2,3-Diphosphoglyceric acid-13C3

2,3-Diphosphoglyceric acid- ¹³C₃ is the ¹³C-labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

HY-B0124S3

Zonisamide-15N,d4

Zonisamide- ¹⁵N,d₄ is the ¹⁵N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

製品番号	製品名		Classification

HY-169157

HDAC6-IN-50		Alkynes
HDAC6-IN-50 (Compound 4) is a potent HDAC6 inhibitor with an IC₅₀ of 35 nM. HDAC6-IN-50 can be used for the study of Parkinson's disease (PD) and Alzheimer's disease (AD) research .

HY-175524

BChE/MAO-B-IN-2		Alkynes
BChE/MAO-B-IN-2 is a dual inhibitor of BChE (IC₅₀ = 0.05 μM, K_i = 0.01 μM) and MAO-B (IC₅₀ = 0.45 μM, K_i = 0.08 μM) with good blood-brain barrier permeability. BChE/MAO-B-IN-2 exhibits antioxidant activity, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. BChE/MAO-B-IN-2 can be used for the study of Alzheimer's disease (AD) .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: